Abstract: Objective: To explore the topoisomerase ⅡA (TOP2A) expression in ovarian cancer and a forecast analysis TOP2A in its possible mechanism and clinical significance in the development of ovarian cancer. Methods: Data on TOP2A gene expression in ovarian cancer tissues were extracted from the Oncomine database. cBioPortal online platform were used to analyze the mutations in TCGA database, and then survival analysis of TOP2A were retrieved from the Kaplan-Meier Plotter tool. Results: A total of 462 TOP2A correlation studies were included, among which 132 showed statistically differences in TOP2A expression, including 125 up-regulated expression and 7 down-regulated expression. Compared with the control group, TOP2A expression in ovarian cancer tissues was higher than that in normal tissues (P＜0.05). TOP2A gene mutation occurred in 12 of 311 epithelial ovarian cancer samples, with a mutation rate of 4%, including amplification in 3 cases, deep loss in 3 cases and truncated mutation occurred in 3 patients. There were 10 proteins related to TOP2A gene, such as DLGAP5, CDC20 and UBE2C. Kaplan-Meier survival analysis showed that the overall survival time and progression-free survival time of ovarian cancer patients with high TOP2A expression were significantly shorter than those with low TOP2A expression (P＜0.05). Conclusions: TOP2A is highly expressed in ovarian cancer and is related to the prognosis of ovarian cancer patients, which might provide a new basis for TOP2A as a novel target for cancer therapy and a new direction for the treatment of ovarian cancer.

Key words: Ovarian neoplasms；, Oncomine；, Cancer genome atlas database；, Topoisomerase ⅡA ；, Survival analysis